Drugs / JUV-161
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07397468 | Feb → Jul 2026 overdue | — | Juvena Therapeutics | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06918925 Comparator | Apr 2025 → Apr 2026 overdue | — | Juvena Therapeutics | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JUV-161 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06918925 ↗ |
| Action | Activate | “JUV-161 is an agonist designed to activate key signaling pathways in skeletal muscle” NCT07397468 ↗ |
| Route | Subcutaneous | “multiple subcutaneous (SC) doses of JUV-161 in healthy volunteers” NCT06918925 ↗ |